Log in to your Inderes Free account to see all free content on this page.
Elicera Therapeutics
6.63 SEK
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+2.00 %
+5.91 %
-7.40 %
+5.24 %
+297.01 %
+272.47 %
+61.71 %
-
+6.94 %
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
321.79M SEK
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13.2.
2026
Annual report '25
5.5.
2026
General meeting '26
5.5.
2026
Interim report Q1'26
All
Research
Press releases
3rd party
ShowingAll content types
BioStock: Extensive positive media coverage for Elicera in Q3
Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio